TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04717739

Intervention type: DEVICE
Intervention: TTFields
Description: Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
Study: NCT05753228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)
Description: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
Study: NCT05984784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Drug: IMG-007 Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Drug: IMG-007 Intravenous Infusion
Study: NCT05753228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)
Description: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)
Description: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chalder Fatigue Scale
Description: The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chalder Fatigue Scale
Description: The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chalder Fatigue Scale
Description: The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Questionnaire (EQ-5D-5L)
Description: The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Questionnaire (EQ-5D-5L)
Description: The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Questionnaire (EQ-5D-5L)
Description: The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems.
Study: NCT04837092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: FR104 treatment administration at day 0, day 14 then every 28 days until month 12
Study: NCT04910542

Intervention type: OTHER
Group type: OTHER
Intervention: Epi-Net Intervention
Description: The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
Study: NCT06199401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular Grafts Eversion and Built-in Technique(XJ-Procedure)
Description: A 1.5-2cm wide bovine pericardial patch and graft ring will be placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft will be intermittently sutured to full layers of aortic vascular with 2-0 pad polyester suture. Finally, the eversion and aortic wall will be continuously sutured together in one more turn.
Study: NCT05357482

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: 300 cGy total body irradiation (TBI, day -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Optimized 4-12 weeks prior to planned transplant date

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: briquilimab
Description: briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: For immune suppression (day -1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
Study: NCT04815746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)-based skills
Description: The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
Study: NCT06005974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules
Study: NCT06475118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometry measurement, myokine dosing, sarcopenia calculation
Description: Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index
Study: NCT06129942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light box
Description: The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light box
Description: The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
Study: NCT06099782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab co-formulated with hyaluronidase
Description: Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab co-formulated with hyaluronidase
Description: Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered via IV infusion
Study: NCT05490043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-101
Description: ATG-101 will be administered intravenously once every 28 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
Study: NCT05442216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp (Cycles 1-2)
Description: 12 mcg/kg intravenously Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 intravenously Days 1-7 (Cycle 3-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp (Cycles 3-12)
Description: 12 mcg/kg intravenously Days 1-3
Study: NCT06567769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1130A
Description: ICV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1130A
Description: ICV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1130A
Description: ICV injection
Study: NCT05753228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton Depression Rating Scale
Description: The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton Depression Rating Scale
Description: The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton Depression Rating Scale
Description: The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
Study: NCT04550039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-weight-supported treadmill
Description: Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso Bionics EksoNR exoskeleton
Description: Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
Study: NCT03106376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% O2 gas in breathed air
Description: Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 26% O2 gas in breathed air
Description: Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask.
Study: NCT05717335

Intervention type: DRUG
Intervention: TachoSil
Description: Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
Study: NCT06566586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3702 tablets+Chemotherapy regimen
Description: TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；
Study: NCT05362578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical accustimulation at treatment point.
Description: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location previously seen to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous electrical accustimulation at sham point.
Description: The transcutaneous electrical accustimulator (TEA) device administers a mild electrical shock through the skin, similar to acupuncture at a location which has not been shown to provide benefit. The precise distinction between sham and experimental accustimulation is not described upon registration to reduce unblinding risk, to maintain scientific integrity.
Study: NCT06454344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Description: CBT-I is a structured program with a robust empirical evidence supporting its efficacy for improving sleep quality and quantity. The cognitive component of CBT-I teaching individuals how to recognize and change the beliefs they hold about sleep that negatively impact sleep, such as negative thoughts and emotions. The behavioral component includes several strategies to help improve sleep, including: improved sleep hygiene, improving the sleep environment, relaxation training, stimulus control therapy (consistent wake/sleep times, using the bed only for sleep, etc), and sleep restriction. Sleep restriction consists of reducing the time spend in bed initially to increase sleep drive in subsequent nights. Once sleep has improved, the time in bed is gradually increased again.
Study: NCT06481774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONNECT platform
Description: CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.
Study: NCT05669833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab (GUS) subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab (GUS) subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: Golimumab (GOL) subcutaneous injection
Study: NCT04751383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05497518

Intervention type: OTHER
Intervention: Observational study - registry
Description: The Network is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
Study: NCT04768673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition
Study: NCT04751383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04768673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
Study: NCT06252298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
Study: NCT06551688

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum 25(OH)D level
Description: The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum 25(OH)D level
Description: The characteristics of 25 (OH) D3 are relatively longer half-life than 1.25 (OH)2 D3, stability, strong detection repeatability, and no biological activity. Generally, systemic levels of the more stable 25 (OH) D3 are considered to be the best index to reflect status of vitamin D in the individual patient
Study: NCT05940012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Hands on treatments including manipulation, mobilization and soft-tissue mobilization with therapeutic intent.
Study: NCT05584566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSSIX Breeze
Description: barrier membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jason membrane
Description: barrier membrane